Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Short term Debt (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Short term Debt readings, the most recent being $450315.0 for Q2 2017.

  • For the quarter ending Q2 2017, Short term Debt fell 91.01% year-over-year to $450315.0, compared with a TTM value of $450315.0 through Jun 2017, down 91.01%, and an annual FY2016 reading of $1.7 million, down 59.69% over the prior year.
  • Short term Debt hit $450315.0 in Q2 2017 for Lisata Therapeutics, down from $3.2 million in the prior quarter.
  • The five-year high for Short term Debt was $5.0 million in Q2 2016, with the low at $216005.0 in Q1 2014.
  • Median Short term Debt over the past 5 years was $2.3 million (2016), compared with a mean of $2.4 million.
  • The sharpest move saw Short term Debt crashed 93.64% in 2014, then skyrocketed 938.39% in 2015.
  • Year by year, Short term Debt stood at $3.3 million in 2013, then crashed by 66.25% to $1.1 million in 2014, then surged by 275.94% to $4.2 million in 2015, then tumbled by 59.69% to $1.7 million in 2016, then crashed by 73.22% to $450315.0 in 2017.
  • According to Business Quant data, Short term Debt over the past three periods came in at $450315.0, $3.2 million, and $1.7 million for Q2 2017, Q1 2017, and Q4 2016 respectively.